0.3838  -0.036 (-8.62%)		10-03 16:00
Open: 0.3997 High: 0.405 Volume: 18,400,489		Pre. Close: 0.42 Low: 0.356 Market Cap: 19(M)

Short term
Mid term
Targets	6-month :	0.51	1-year :	0.69
Resists	First :	0.44	Second :	0.59
Pivot price	0.37
Supports	First :	0.2	Second :	0.16
MAs	MA(5) :	0.3	MA(20) :	0.39
	MA(100) :	0.38	MA(250) :	4.63
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	51.7	D(3) :	29.2
RSI	RSI(14): 48.3
52-week	High :	15.8	Low :	0.2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ASBP ] has closed below upper band by 48.6%. Bollinger Bands are 12.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.41 - 0.41	0.41 - 0.41
Low:	0.35 - 0.35	0.35 - 0.36
Close:	0.38 - 0.38	0.38 - 0.39

Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.

Fri, 03 Oct 2025
Why Actelis Networks Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Thu, 02 Oct 2025
Morning Market Movers: ASBP, FICO, ESLA See Big Swings - RTTNews

Thu, 02 Oct 2025
Aspire Biopharma outlines pipeline milestones for drug delivery tech By Investing.com - Investing.com Australia

Wed, 01 Oct 2025
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication - ACCESS Newswire

Wed, 01 Oct 2025
Breakthrough 2-Minute Heart Attack Treatment: Aspire's Sublingual Aspirin Beats Standard Tablets in Clinical Tests - Stock Titan

Fri, 26 Sep 2025
Aspire Biopharma completes $1 million funding tranche and changes auditor - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	50 (M)
Shares Float	34 (M)
Held by Insiders	45 (%)
Held by Institutions	4.6 (%)
Shares Short	2,260 (K)
Shares Short P.Month	1,290 (K)

EPS	-0.62
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.19
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-64.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	13 (M)

PE Ratio	-0.63
PEG Ratio	0
Price to Book value	-2.02
Price to Sales	0
Price to Cash Flow	-6.54

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.